Reportedly, Eli Lilly (LLY), an American pharmaceutical company is expected to grab a significant share of Pfizer’s (PFE) breast cancer treatment market after the completion of a successful Phase 3 study of Verzenio. The researchers at Eli Lilly tested Verzenio in combination with standard endocrine therapy, and in comparison to endocrine therapy alone the treatment “significantly” performed better to reduce the chances of cancer relapse for a specific patient group. The company is now planning to submit data from this study to regulatory authorities worldwide possibly leading to the cancer treatment’s approval in 2021.
Earlier this month, Pfizer’s Ibrance breast cancer treatment failed to show promising results as an early-stage breast cancer treatment. Pfizer tested the drug on patients with a greater risk of relapsing. Both Ibrance and Verzenio belong to the same class of drugs. LLY stock rose by 15.7% to close at 163.71, whereas shares of Pfizer edged 0.1% higher to 33.40 after the results of the successful phase 3 study.
“It is very likely that Verzenio will have this large indication (use) in their level and Ibrance will not. The high likelihood is that Lilly’s share of the CDK4/6 market will grow and Pfizer’s will decline.” stated SVB Leerink analyst Geoffrey Porges in a report to clients.
“When a person is diagnosed with high-risk early-stage breast cancer, they strive to do everything in their power to prevent a recurrence. And as clinicians, we have the same goal,” stated Maura Dickler, Vice President of one of Lilly’s oncology divisions.
Approximately, 30% of patients with this form of breast cancer are at risk of recurrence, informed Lilly and Verzenio could start taking over share from Pfizer’s Ibrance.
“But Verzenio’s future upfront use is likely to threaten this sales growth, and could even lead to declining sales of Ibrance after 2021, as patients are unlikely to be exposed to two CDK4/6 inhibitors without supportive data for the effect of re-treatment,” added Geoffrey Porges based on The Street estimates of Ibrance sales of $5 billion in 2019 growing to $7.9 billion in 2024.
If you found this story to be interesting then please check out Seattle-based Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Please visit the Atossa Therapeutics (ATOS) page at Vista Partners to keep up with their progress and to learn more daily about their work and developments in diagnosing and treating breast cancer.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.